Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnostic agent for liver function

a liver function and diagnostic agent technology, applied in the field of diagnostic agents for liver function, can solve the problems of insufficient quantitative determination of liver enzymes as test methods, decreased liver enzyme leakage, and problems, and achieve the effect of imposing less physical burden on subjects and being used safely without side effects

Inactive Publication Date: 2000-06-06
TOKYO GAS CO LTD
View PDF6 Cites 73 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

According to the present invention, there is provided a diagnostic agent for liver function which imposes less physical burden on a subject, can give accurate test results immediately, and can be used safely without side effects. The diagnostic agent of the invention is useful for evaluating the liver function at the test time.

Problems solved by technology

However, in the case of patients suffering from chronic hepatitis or cirrhosis whose liver function is remarkably lowered, enzyme leakage from the liver decreases since the amounts of enzymes present in the liver tissue decrease.
Therefore, quantitative determination of these enzymes is insufficient as a test method to evaluate the degree of a liver function disorder.
However, these tests have problems, respectively (Practice of Diagnosis & Treatment in Digestive Apparatuses 1: Diagnostic Approach to Hepatic Disorders, Teruyuki Ohkubo (Ed.
Besides, it is difficult to follow those processes in which liver function changes drastically for a short period of time after a hepatic operation.
In ICG tolerance test, reliable results cannot be obtained when bilirubin levels are high, because ICG competes with bilirubin when it is taken into liver cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic agent for liver function
  • Diagnostic agent for liver function
  • Diagnostic agent for liver function

Examples

Experimental program
Comparison scheme
Effect test

example 1

Method of Breath Test

(1) Preparation of Rats with Acute Hepatitis

As test animals, male Sprague-Dawley (SD) rats were purchased from Nippon Charles River K.K. They were bred at 23.+-.2.degree. C. under 55.+-.10% humidity before use. These rats (7-10 week-old) were anesthetized by intraperitoneal administration of Nembutal (50 mg / kg) and then intraperitoneally administered galactosamine hydrochloride (200 mg / ml physiological saline) at a dose of 0.6-1.2 g / kg [Koff, S. et al., Proc. Soc. Exptl. Med. 137:696 (1971); Keppler, D. et al., Exp. Mol. Pathology, 9:279 (1968); Creation of Model Animals (by Disease) and Experimental Methods for Development of New Drugs, supervised by Masaharu Uchitaka, p. 126 (1993)]. Two days thereafter, blood was collected from the tail vein, and serum was separated from the blood. Glutamic pyruvic transaminase activity (GPT) and the total amount of bilirubin in the serum were measured using Fuji Drychem FDC5500.

(2) .sup.13 C Breath Test

A breath test was carr...

example 2

1-.sup.13 C-Galactose Breath Test

1-.sup.13 C-galactose (purchased from ICON) dissolved in physiological saline was administered to healthy rats (8-week-old; total bilirubin value.ltoreq.0.5 mg / dl; n=3) and rats with acute hepatitis (8-week-old; total bilirubin value.gtoreq.2.8 mg / dl; n=3) from the femoral vein at a dose of 100 mg / kg. Then, degrees of increase of .sup.13 C levels in exhaled CO.sub.2 (.DELTA..sup.13 C (.Salinity.)) were measured according to the method described in Example 1.

.DELTA..sup.13 C values (.Salinity.) continued increasing up to 20 min after the administration of 1-.sup.13 C-galactose in both the healthy and the hepatitic rats (FIG. 2).

The .DELTA..sup.13 C value (.Salinity.) at 20 min after the administration was 12.68.+-.6.25.Salinity. in the hepatitic rats, while the value was 42.43.+-.3.75.Salinity. in the healthy rats. Thus, the value in the hepatitis rats was very significantly (p<0.01 (ANOVA with Fischer LSD)) lower than that in the healthy rats.

The slo...

example 3

1-.sup.13 C-Glucose Breath Test

1-.sup.13 C-glucose (purchased from CIL) dissolved in physiological saline was administered to healthy rats (8-week-old; total bilirubin value.ltoreq.0.6 mg / dl; n=4) and rats with acute hepatitis (8-week-old; total bilirubin value>3 mg / dl; n=4) from the femoral vein at a dose of 100 mg / kg. Then, degrees of increase of .sup.13 C levels in exhaled CO.sub.2 (.DELTA..sup.13 C (.Salinity.)) were measured according to the method described in Example 1.

.DELTA..sup.13 C values (.Salinity.) continued increasing up to 20 min after the administration of 1-.sup.13 C-glucose in both the healthy and the hepatitic rats (FIG. 3).

The .DELTA..sup.13 C value (.Salinity.) at 5 min after the administration was 48.90.+-.2.97.Salinity. in the hepatitic rats, while the value was 39.37.+-.4.02.Salinity. in the healthy rats. Thus, the value in the hepatitis rats was significantly (p<0.05 (ANOVA with Fischer LSD)) higher than that in the healthy rats.

The slope of increase of .DE...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a diagnostic agent for liver function, comprising a compound labelled with 13C at least at one specific position selected from the group consisting of the following (a) to (f): (a) galactose, glucose or xylose labelled with 13C at least at one specific position or a starch composed of glucose units labelled with 13C at least at one specific position; (b) a polar amino acid, heterocyclic amino acid, isoleucine or valine labelled with 13C at least at one specific position; (c) a carboxylic acid constituting the glycolytic pathway or the citric acid cycle, labelled with 13C at least at one specific position; (d) a fatty acid labelled with 13C at least at one specific position; (e) a glyceride labelled with 13C at least at one specific position; and (f) glycerol labelled with 13C at least at one specific position. According to the present invention, a diagnostic agent for liver function which imposes less physical burden on a subject, can give accurate test result immediately, and can be used safely without side effects is provided. The diagnostic agent of the invention is useful for evaluating the liver function of a subject at the time when the test is carried out.

Description

The present invention relates to a diagnostic agent for liver function. More specifically, the invention relates to a diagnostic agent for liver function, comprising a compound labelled with .sup.13 C at least at one specific position.DESCRIPTION OF THE PRIOR ARTTest methods generally used in the screening of liver function disorder are blood biochemical tests to quantitatively determine enzymes such as transaminases (GPT and GOT), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in blood. These enzymes leak out from the liver tissue of a patient into the blood when he / she has a liver function disorder. Among all, GPT and GOT are enzymes mainly present in the liver. While their blood levels are low under normal conditions, the levels increase remarkably at the time of liver function disorders. Thus, GPT and GOT are excellent indicators which detect liver function disorders sensitively. However, in the case of patients suffering from chronic hepatitis or cirrhosis whose liv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K51/12A61K51/04
CPCA61K51/1206
Inventor KOHNO, TADASHIHOSOI, ISABUROOHSHIMA, JUNKOITO, ASUKASHIBATA, KUNIHIKO
Owner TOKYO GAS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com